相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients
Kai Wille et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2022)
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients
Tiziano Barbui et al.
LEUKEMIA (2021)
Association between myelofibrosis and thromboembolism: A population-based retrospective cohort study
Walid Saliba et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
Paola Guglielmelli et al.
BLOOD CANCER JOURNAL (2020)
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
Tarinee Rungjirajittranon et al.
BMC CANCER (2019)
Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis
Alberto Alvarez-Larran et al.
ANNALS OF HEMATOLOGY (2019)
Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms A Population-Based Cohort Study
Malin Hultcrantz et al.
ANNALS OF INTERNAL MEDICINE (2018)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients
Nicola Polverelli et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan
Katsuto Takenaka et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients
F. Passamonti et al.
LEUKEMIA (2017)
NCCN Guidelines® Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines
Ruben A. Mesa et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Myeloproliferative neoplasms: from origins to outcomes
Jyoti Nangalia et al.
BLOOD (2017)
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
Jelena D. Milosevic Feenstra et al.
BLOOD (2016)
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
A. Kaifie et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists
V. De Stefano et al.
LEUKEMIA (2016)
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia
Juan-Carlos Hernandez-Boluda et al.
ANNALS OF HEMATOLOGY (2015)
Myeloproliferative Neoplasms A Contemporary Review
Ayalew Tefferi et al.
JAMA ONCOLOGY (2015)
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis
M. C. Finazzi et al.
LEUKEMIA (2015)
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients
Veronika Buxhofer-Ausch et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
Hans Carl Hasselbalch
BLOOD (2012)
Improving Survival Trends in Primary Myelofibrosis: An International Study
Francisco Cervantes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study
Malin Hultcrantz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
G. Finazzi et al.
LEUKEMIA (2012)
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis
Elias Jabbour et al.
BLOOD (2011)
A phase-2 trial of low-dose pomalidomide in myelofibrosis
K. H. Begna et al.
LEUKEMIA (2011)
Thrombosis in primary myelofibrosis: incidence and risk factors
Tiziano Barbui et al.
BLOOD (2010)
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alberto Alvarez-Larran et al.
BLOOD (2010)
Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked
Michelle Ann Elliott et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution
F Cervantes et al.
LEUKEMIA (2006)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
